Blood clot risk prediction for lung cancer patients on immunotherapy
Part of Cancer, Heart & circulation, Lungs & breathing clinical trials.
This study builds a tool to predict blood clot risk in lung cancer patients receiving immune checkpoint inhibitors. Researchers will use your data to develop a more personalized risk assessment, which may help prevent dangerous clots during treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed lung cancer diagnosis (based on tissue sample).
- You must have received at least one dose of an immune checkpoint inhibitor approved in China for lung cancer.
- You must agree to participate by signing a consent form.
- You cannot have had a blood clot (in veins or arteries) right before starting the immunotherapy.
- You cannot have two or more different cancers at the same time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether doctors can predict blood clots in people with certain cancers who are receiving chemotherapy. If you have ovarian, lung, stomach, or pancreatic cancer and are starting chemotherapy, you may be able to join and help improve clot prevention.
This study looks at how well blood thinners (anticoagulants) work in people with cancer who have had a blood clot. It aims to compare the benefits and risks of different anticoagulant medicines.
This study tests whether a blood test and computer program can help doctors decide how long you need to take blood thinners after a cancer-related blood clot. If you've been on a blood thinner for a few months and have certain cancers, this trial may offer a more personalized approach.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
This study looks at whether certain gene profiles in advanced lung cancer affect the risk of blood clots. It may help doctors better understand and prevent clots in people starting new cancer treatment.
This trial studies how your blood's ability to clot changes over time in people with certain cancers who have not yet started treatment. The goal is to better predict who might develop a dangerous blood clot, so that preventative steps can be taken.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.